RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 147 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,054,335 | +36.9% | 45,990 | -1.5% | 0.00% | 0.0% |
Q2 2023 | $770,022 | +100.8% | 46,696 | +117.3% | 0.00% | 0.0% |
Q1 2023 | $383,382 | -32.1% | 21,490 | +10.9% | 0.00% | 0.0% |
Q4 2022 | $564,345 | +17.6% | 19,380 | -1.0% | 0.00% | 0.0% |
Q3 2022 | $480,000 | +507.6% | 19,580 | +3.3% | 0.00% | – |
Q2 2022 | $79,000 | -73.9% | 18,961 | -28.1% | 0.00% | – |
Q1 2022 | $303,000 | -58.9% | 26,366 | -64.3% | 0.00% | -100.0% |
Q4 2021 | $738,000 | -58.0% | 73,913 | -45.1% | 0.00% | -66.7% |
Q3 2021 | $1,757,000 | -50.5% | 134,586 | -25.8% | 0.00% | -40.0% |
Q2 2021 | $3,552,000 | +42.5% | 181,414 | +54.7% | 0.01% | +25.0% |
Q1 2021 | $2,493,000 | +618.4% | 117,233 | +905.9% | 0.00% | +300.0% |
Q4 2020 | $347,000 | +30.5% | 11,654 | +36.5% | 0.00% | 0.0% |
Q2 2018 | $266,000 | – | 8,538 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |